Business
Admission to AIM and first day of dealings
Admission to AIM and first day of dealings.
About this update from Fusion Antibodies Plc
[{"type":"text","content":"\n \nRNS Number : 5710Z Fusion Antibodies PLC 18 December 2017 \n\nFusion Antibodies plc \n(\"Fusion\" or the \"Company\")\n \nAdmission to trading on AIM and First Day of Dealings\n \nFusion Antibodies (AIM: FAB), a contract research organisation (\"CRO\") providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications, announces the admission of its ordinary shares (\"Ordinary Shares\") to trading on AIM (\"Admission\") today, 18 December 2017. Dealings in the Ordinary shares will commence under the ticker \"FAB\" and ISIN GB00BDQZGK16.\n \nThe Company's Admission Document is available from www.fusionantibodies.com.\n \nThe Company has successfully raised £5.5 million (before expenses) through a placing of new Ordinary Shares, to fund the expansion of its existing laboratory space, increase its sales and marketing efforts, for the development of the new service lines, as well as providing additional working capital. In addition, £1.1 million has been raised for selling shareholders.\n \nTransaction highlights\n \n· £5.5 million raised by the conditional placing of 6,707,317 new Ordinary Shares at a placing price of 82p\n· The new Ordinary Shares represent c. 30.4 per cent. of the enlarged share capital on Admission\n· Selling shareholders have sold 1,310,976 existing Ordinary Shares as part of the placing\n· Enlarged share capital on Admission of 22,091,192 Ordinary Shares\n· £18.1 million market capitalisation on Admission at the placing price\n· Allenby Capital Limited is Nominated Adviser and Broker\n \nAbout Fusion Antibodies plc\n \nFusion is a Belfast based, revenue generating and profitable CRO providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications. The Company provides a broad range of services in antibody generation, development, production, characterisation and optimisation. These services include antigen expression, antibody production, purification and sequencing, antibody humanisation using Fusion's proprietary CDRxTM platform and the production of ant...